LRMR Larimar Therapeutics, Inc.
USHealthcareAs of 2026-08-24
Why LRMR matters now
Larimar Therapeutics, Inc. (LRMR) is a US stock in Healthcare. The latest InvestLog snapshot shows $4.05 with -3.11% on the session and $420.7M in market capitalization; recent performance reads 1-month +9.31% and YTD -4.46%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-29.6M, and EPS of $-0.35. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -42.2%.
The latest indexable market news headline is "Dimensional Fund Advisors LP Purchases 470,968 Shares of Larimar Therapeutics, Inc. LRMR" from Defense World.
Additional event context on this page matters because analyst consensus is Buy with a median target of $12.00; recent insider activity includes Hamilton Thomas Edward filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.96
P/S
0.00
EV/EBITDA
-0.83
DCF Value
$1.06
FCF Yield
-42.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-134.1%
ROA
-79.6%
ROIC
-106.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-29.6M | $-0.35 |
| Q4 2025 | $0.00 | $-62.5M | $-0.73 |
| FY 2025 | $0.00 | $-165.7M | $-2.27 |
| Q3 2025 | $0.00 | $-47.7M | $-0.61 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$12.00
Target (Median)
$12.00
Target Range
$12.00 - $12.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.82
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.